Is RBGLY a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Emerging markets as the growth engine, with net revenue (fy 2025, group) at ~£14.2 billion. The bear case rests on litigation is the risk that sets Reckitt apart from its peers. Analysts covering it are spread from $14.37 to $18.66, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Litigation is the risk that sets Reckitt apart from its peers. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $14.37, +4.8% from the $13.71 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Emerging markets as the growth engine. Emerging markets are now Core Reckitt's largest region, at ~£1.09 billion of net revenue in the March 2026 quarter, and they grew 14.6% like-for-like in 2025 with double-digit gains in China and India, and also in Indonesia and Colombia. The most optimistic analyst target on RBGLY is $18.66, +36.1% from the $13.71 price. That figure is only reachable if this thesis works close to its best case.

Litigation is the risk that sets Reckitt apart from its peers. Mead Johnson and Abbott face more than 2,000 lawsuits in the US alleging that formula for premature babies is linked to necrotizing enterocolitis, a serious bowel disease. Mead Johnson has recently won: a federal bellwether jury found for it, a St. Louis jury cleared it in July 2026, and an Illinois appeals court threw out a $60 million verdict from March 2024 and sent the case back for retrial. Abbott has fared worse, including a $495 million verdict upheld on appeal in Missouri, which shows how large single awards can be. Reckitt denies that its products cause NEC, but more trials are ahead and a run of losses could cost far more than the reserves investors assume. Operating risks are also real. Core growth slowed to 1.3% in the March 2026 quarter, Europe is shrinking, Household Care fell 7.6%, and the cold and flu season can swing Self Care in any quarter. Russia sanctions changes and the Middle East conflict hit emerging markets in early 2026, and the transfer of the Russian business is still in progress. Higher oil prices could add ~£130 million to £150 million to input costs, and a Mead Johnson sale may fetch less than hoped while the lawsuits remain open. For US holders, RBGLY's dollar price moves with sterling, dividends are reduced by depositary fees, and OTC volume can be lighter than the London line. The most pessimistic published target is $14.37, +4.8% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

British maker of consumer health, hygiene and home brands including Dettol, Lysol, Durex, Finish and Mucinex, plus Mead Johnson infant formula.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Emerging markets as the growth engine) stalling in the reported numbers rather than in the narrative, the risk above (litigation is the risk that sets Reckitt apart from its peers) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

RBGLY is a sponsored American depositary receipt for Reckitt Benckiser Group plc, the British consumer health and hygiene company behind Dettol, Lysol, Durex, Finish and Mucinex. It trades over the counter on the OTC Pink tier in US dollars. Reckitt's main listing is on the London Stock Exchange under the ticker RKT.

Reckitt's market value divided by the RBGLY price works out to about five ADRs per London ordinary share, so each ADR represents roughly one-fifth of a share. Holders who want the exact ratio and fee schedule can check the depositary's program page or Reckitt's ADR information on its investor-relations site.

Yes. Reckitt pays an interim dividend in the autumn and a final dividend after its annual meeting. The 2025 total was 212.2p per share, up 5%, and the 2026 interim was raised another 5%. It also paid a £1.6 billion special dividend in February 2026. Yahoo Finance showed RBGLY's forward yield at ~4.2%, with the latest ex-dividend date on August 10, 2026.